An open-label study of aripiprazole in children with a bipolar disorder.

ABSTRACT: The purpose of this open-label study was to describe the effectiveness of aripiprazole (APZ) in the treatment of children with bipolar disorders suffering from manic symptomatology.Symptomatic outpatients (Young Mania Rating Scale [YMRS] score ?15) meeting strict, unmodified, Diagnostic and Statistical Manual of Mental Disorders, 4th edition, diagnostic symptom criteria for a bipolar disorder, ages 4-9 years, were eligible. Subjects were treated prospectively with flexible doses of APZ (maximum daily dose of 15?mg/day), for up to 16 weeks or until a priori response criteria were met. Outcome measures included the YMRS, Clinical Global Impressions Scale-Severity, Children's Global Assessment Scale (CGAS), and the Children's Depression Rating Scale-Revised (CDRS-R). A priori response criteria consisted of 3 of 4 consecutive weeks with (1) CDRS-R <29; (2) YMRS <10; and (3) CGAS >50.Ninety-six children (62 males; mean age of 6.9 (SD?=?1.7), received APZ for an average length of treatment of 12.5 (SD?=?3.9) weeks. Significant improvements in YMRS, CDRS-R, CGAS, and Clinical Global Impressions Scale-Severity scores (p?

SUBMITTER: Findling RL 

PROVIDER: S-EPMC3192054 | biostudies-literature | 2011 Aug

REPOSITORIES: biostudies-literature